

1 "This accepted author manuscript is copyrighted and published by Elsevier. It is posted here by
2 agreement between Elsevier and MTA. The definitive version of the text was subsequently published in
3 Molecular Immunology, 2016 Apr;72:37-48. doi: 10.1016/j.molimm.2016.02.011. Available under license
4 CC-BY-NC-ND."

5

6

7 **Complement factor H modulates the activation of human neutrophil granulocytes and the**
8 **generation of neutrophil extracellular traps**

9 Andrea E. Schneider,^a Noémi Sándor,^b Éva Kárpáti,^a Mihály Józsi^a

10

11 ^a MTA-ELTE "Lendület" Complement Research Group, Department of Immunology, Eötvös
12 Loránd University, 1117 Budapest, Hungary;

13 ^b MTA-ELTE Immunology Research Group, Department of Immunology, Eötvös Loránd
14 University, 1117 Budapest, Hungary

15

16 **Corresponding author:** Mihály Józsi, MTA-ELTE "Lendület" Complement Research Group,
17 Department of Immunology, Eötvös Loránd University, Pázmány Péter sétány 1/c, H-1117
18 Budapest, Hungary; Phone: +36 1 3812175; Fax: +36 1 3812176; E-mail: mihaly.jozsi@gmx.net.

19

20 This work was presented in part at the 15th European Meeting on Complement in Human Disease,
21 27-30 June, 2015, Uppsala, Sweden (Mol. Immunol. 2015, 67: 179.).

22

23 **Abbreviations:** CR3, complement receptor type 3 (CD11b/CD18); DHR, dihydrorhodamine;
24 DIC, differential interference contrast; FH, factor H; Fn, fibronectin; HSA, human serum
25 albumin; NET, neutrophil extracellular trap; ROS, reactive oxygen species.

26
27 **Author contributions:** M.J. initiated and supervised the study. A.E.S., N.S. and M.J. designed
28 the experiments. A.E.S., N.S. and É.K. performed experiments. A.E.S., N.S., É.K. and M.J.
29 analyzed the data. A.E.S. and M.J. wrote the manuscript with the help of the other authors.

30
31

32 **Abstract**

33 Factor H (FH) is a major inhibitor of the alternative pathway of complement activation in plasma
34 and on certain host surfaces. In addition to being a complement regulator, FH can bind to various
35 cells via specific receptors, including binding to neutrophil granulocytes through complement
36 receptor type 3 (CR3; CD11b/CD18), and modulate their function. The cellular roles of FH are,
37 however, poorly understood. Because neutrophils are important innate immune cells in
38 inflammatory processes and the host defence against pathogens, we aimed at studying the effects
39 of FH on various neutrophil functions, including the generation of extracellular traps. FH co-
40 localized with CD11b on the surface of neutrophils isolated from peripheral blood of healthy
41 individuals, and cell-bound FH retained its cofactor activity and enhanced C3b degradation.
42 Soluble FH supported neutrophil migration and immobilized FH induced cell spreading. In
43 addition, immobilized but not soluble FH enhanced IL-8 release from neutrophils. FH alone did
44 not trigger the cells to produce neutrophil extracellular traps (NETs), but NET formation induced
45 by PMA and by fibronectin plus fungal β -glucan were inhibited by immobilized, but not by
46 soluble, FH. Moreover, in parallel with NET formation, immobilized FH also inhibited the
47 production of reactive oxygen species induced by PMA and by fibronectin plus β -glucan.
48 Altogether, these data indicate that FH has multiple regulatory roles on neutrophil functions.
49 While it can support the recruitment of neutrophils, FH may also exert anti-inflammatory effects

50 and influence local inflammatory and antimicrobial reactions, and reduce tissue damage by
51 modulating NET formation.

52

53 **Keywords:** complement; CR3; factor H; extracellular DNA; neutrophil extracellular trap;
54 reactive oxygen species

55

56

57 **1. Introduction**

58 The complement system is a major humoral component of innate immunity and plays important
59 roles in antimicrobial defense and in maintaining host homeostasis (Ricklin et al., 2010).

60 Complement components and their activation fragments generated upon triggering of the
61 complement cascade also influence the activation and function of various cells through several
62 receptors (Ricklin et al., 2010).

63 Factor H (FH) is a major inhibitor of the alternative pathway of complement in plasma and on
64 host cellular and non-cellular surfaces (Ferreira et al., 2010; Kopp et al., 2012; Rodriguez de
65 Cordoba et al., 2004). FH is a 155-kDa glycoprotein that is mainly produced in the liver and
66 reaches a median plasma concentration of ~250 µg/ml (Kopp et al., 2012). FH is also produced
67 locally by several types of cells, such as endothelial cells, monocytes and dendritic cells
68 (Brooimans et al., 1990; Li et al., 2011; Whaley, 1980). FH regulates complement activation at
69 the level of the central C3b component by acting as a cofactor in the cleavage of C3b by factor I
70 and by inhibiting formation and accelerating the decay of the alternative pathway C3 convertase
71 enzyme (Kopp et al., 2012; Rodriguez de Cordoba et al., 2004).

72 In addition to being a complement inhibitor, there is growing evidence for direct regulatory
73 roles of FH on several cell types. FH has been shown to bind to neutrophil granulocytes via

74 complement receptor type 3 (CR3; CD11b/CD18), and mediate adhesion and cell polarization
75 (Avery and Gordon, 1993; DiScipio et al., 1998; Losse et al., 2010). *Candida albicans*-bound FH
76 facilitated fungal recognition and antifungal responses by neutrophil granulocytes (Losse et al.,
77 2010). FH bound to *Streptococcus pneumoniae* was shown to mediate interaction of
78 pneumococci with human neutrophils and epithelial cells, and facilitate the entry into host cells
79 (Agarwal et al., 2010b). Moreover, FH was shown to facilitate adherence of *Neisseria*
80 *gonorrhoeae* to CR3-expressing CHO-cells (Agarwal et al., 2010a). FH also binds to monocytes,
81 macrophages, B cells and platelets (Hartung et al., 1984; Iferroudjene et al., 1991; Lambris et al.,
82 1980; Vaziri-Sani et al., 2005). FH promotes the uptake of apoptotic cells by macrophages in a
83 non-inflammatory manner (Mihlan et al., 2009) and has a chemotactic function on monocytes
84 (Nabil et al., 1997). It was also shown that CR3 is involved in FH binding to monocytes and FH
85 can inhibit the C1q-mediated uptake of apoptotic cells (Kang et al., 2012). On B cells, FH was
86 reported to inhibit immunoglobulin secretion and cell differentiation (Tsokos et al., 1985), but the
87 B cell FH receptor could not be identified at the molecular level (Erdei and Sim, 1987). However,
88 these non-canonical, cellular roles of FH are poorly understood.

89 Neutrophil granulocytes are major inflammatory cells and key players during infections, since
90 they provide the first line of host cellular defense (Mocsai, 2013; Nathan, 2006). They are rapidly
91 recruited to infected tissues and have several killing mechanisms to eliminate pathogens
92 (Kolaczkowska and Kubes, 2013). In addition to phagocytosis and intracellular killing, and the
93 release of antimicrobial factors, neutrophils can trap microorganisms by releasing neutrophil
94 extracellular traps (NETs) (Brinkmann et al., 2004; Nathan, 2006). These web-like structures are
95 formed by activated neutrophils and composed of nuclear chromatin associated with nuclear
96 histones and granular antimicrobial proteins (Brinkmann et al., 2004). Thus, NETs probably do
97 not only function as a trap, but they are also able to play a direct role in killing pathogens

98 (Brinkmann et al., 2004; Kolaczowska and Kubes, 2013). NETs are formed in response to a
99 variety of pro-inflammatory stimuli, such as LPS, IL-8 and TNF- α , as well as several
100 microorganisms (Brinkmann et al., 2004; Remijsen et al., 2011). In vitro, phorbol 12-myristate
101 13-acetate (PMA) is considered the most potent agent to induce NET formation (Brinkmann et
102 al., 2004; Remijsen et al., 2011). In addition to particularly hyphal forms of fungi (Svobodova et
103 al., 2012; Urban et al., 2006), immobilized, purified fungal β -glucan together with fibronectin as
104 an extracellular-matrix component can also stimulate NET formation (Byrd et al., 2013).
105 However, NETs represent not only an effective protection when phagocytosis is not possible due
106 to the large size of microbes (Branzk et al., 2014), but could also be a potential
107 immunostimulatory agent if NET elimination is not completely performed under non-infectious
108 conditions (Farrera and Fadeel, 2013; Leffler et al., 2013; Mocsai, 2013). In addition to the
109 prolonged inflammatory environment and continuous tissue damage, NETs can contribute to the
110 production of autoantibodies (e.g., anti-dsDNA and anti-histones), which may play a role in
111 autoimmune and inflammatory diseases (Leffler et al., 2013; Mantovani et al., 2011; Saffarzadeh
112 and Preissner, 2013; Sur Chowdhury et al., 2014).

113 The FH receptor CR3 is also a main receptor for recognizing fungal ligands, including β -
114 glucan, on human neutrophils (Losse et al., 2011; Ross et al., 1987; van Bruggen et al., 2009) and
115 it also plays an essential role in immune-complex induced (Behnen et al., 2014) and β -glucan
116 plus fibronectin-induced formation of NETs (Byrd et al., 2013). The present study was designed
117 to investigate the role of FH in modulating the activation and cellular functions of human
118 neutrophils, particularly the generation of NETs.

119

120 **2. Materials and methods**

121 **2.1. Materials**

122 Purified human FH, C3b, factor I, and polyclonal goat anti-human FH antibody were purchased
123 from Merck Ltd. (Budapest, Hungary). Human iC3b was obtained from Complement Technology
124 Inc. (Tyler, Texas). Bovine serum albumin (BSA) was from Applichem (Darmstadt, Germany)
125 and human serum albumin (HSA) was from Sigma-Aldrich Inc. (St. Louis, MO). Horseradish
126 peroxidase (HRP)-conjugated goat anti-human C3 antibody was obtained from MP Biomedicals
127 (Solon, OH). HRP-conjugated rabbit anti-goat immunoglobulins and goat anti-mouse
128 immunoglobulins were from Dako (Hamburg, Germany).

129

130 **2.2. Cells**

131 Human neutrophil granulocytes were isolated from peripheral blood of healthy individuals. All
132 blood donors gave informed consent. In some cases, neutrophils were isolated from buffy coats
133 obtained from healthy blood donors and provided by the Hungarian National Blood Transfusion
134 Service. The studies were approved by the respective national authority (TUKEB ETT,
135 permission number 838/PI/12). Mononuclear cells were removed by Ficoll-Hypaque (Sigma-
136 Aldrich) density gradient centrifugation, then dextran sedimentation using Dextran T-500
137 (Pharmacia Fine Chemicals, Uppsala, Sweden) was performed. Red blood cells were lysed in
138 hypotonic buffer. Purity of isolated neutrophils was analyzed by flow cytometry using anti-CD16
139 and anti-CD14 antibodies (BD Biosciences, Heidelberg, Germany) and was over 95%.

140

141 **2.3. Colocalization assay**

142 FH binding to neutrophils was analyzed by flow cytometry as previously described (Losse et al.,
143 2010). To measure colocalization between FH and CD11b, 10^6 neutrophils were first incubated

144 with 50 µg/ml FH for 30 min at 22°C in modified Hank's buffer (142 mM NaCl, 1 mM Na₂SO₄,
145 5 mM KCl, 1 mM NaH₂PO₄, 1 mM MgCl₂, 2.5 mM CaCl₂, 5 mM glucose, 10 mM HEPES; pH
146 7.4). After washing with PBS, Fc receptor blocking reagent (Miltenyi Biotec, Bergisch Gladbach,
147 Germany) was added to reduce nonspecific Ab binding, then a goat anti-human FH antibody
148 (1:500 in PBS containing 1% FBS) was added for 30 min at 4°C, followed by Alexa-488-
149 conjugated rabbit anti-goat Ig (Molecular Probes-Invitrogen, Carlsbad, CA) for 30 min at 4°C.
150 For detection of CR3, CD11b was labelled with biotinylated anti-CD11b (clone M1/70.15;
151 Molecular Probes-Invitrogen) and streptavidin-PE (Sigma-Aldrich). The colocalization was
152 quantified by calculating Pearson's correlation coefficients from at least 100 cells in each sample
153 (Adler and Parmryd, 2010).

154

155 **2.4. Cellular cofactor assay**

156 2×10^6 neutrophils were incubated with 10 µg/ml FH for 30 min at 22°C in modified Hank's
157 buffer. After washing twice with PBS to remove unbound FH, 3 µg/ml purified C3b and 5 µg/ml
158 factor I were added to the cells in 200 µl final volume in PBS and incubated for 1 h at 37°C. The
159 supernatants were separated on 10% SDS-PAGE gel, transferred to nitrocellulose membrane and
160 analyzed by Western blot using HRP-conjugated anti-C3 antibody to detect cleaved C3b
161 fragments. As a positive control for cofactor activity, FH, C3b and factor I were mixed together
162 in PBS, without cells. The blots were developed by enhanced chemiluminescence (Merck-
163 Millipore).

164

165 **2.5. Calcium measurement by flow cytometry and microscopy**

166 Neutrophils were washed and incubated for 30 min at 37°C in 5 µg/ml Fluo-4 AM (Molecular
167 Probes-Invitrogen) solution in RPMI-1640 medium (Sigma-Aldrich). After loading with the dye,

168 samples were washed and resuspended in Hank's buffer. 50 µg/ml FH and 2 µg/ml ionomycin
169 (Sigma-Aldrich) as a positive control were used to raise cytoplasmic free calcium level.
170 Fluorescence measurements were performed using a FACS Calibur flow cytometer (BD
171 Biosciences) with an air-cooled argon ion laser (488 nm excitation) and red diode laser (632 nm
172 excitation). Data collection and analysis were done with CellQuest Pro software. Dead cells were
173 excluded by negative gating based on propidium iodide uptake.

174 To investigate the calcium response induced by immobilized FH, neutrophils loaded with
175 Fluo-4-AM were placed into wells of Ibidi microplates (Ibidi, Planegg/Martinsried, München,
176 Germany) at 1.5×10^6 / 200 µl density. Microplates were previously coated overnight at 22°C
177 with 50 µg/ml FH or BSA. Changes in fluorescence intensity of individual cells were monitored
178 for 20 min in Olympus FluoView 500 laser-scanning confocal microscope (excitation: 488 nm)
179 with x60 objective, in time-resolved acquisition mode (1.13 s/frame) immediately after placing
180 them to the microplate. 37°C, 5% CO₂ and humidity were provided by Ibidi gas incubation
181 system for live cell imaging. During data analysis, mean fluorescence intensities obtained from
182 single cell recordings were normalized to differential interference contrast (DIC) intensities to
183 avoid out of focus intensity alteration effects.

184

185 **2.6. Measurement of neutrophil spreading by confocal microscopy**

186 Lab-Tek borosilicate chambered coverglass microplates (NUNC, Rochester, NY) were coated
187 with 50 µg/ml FH or BSA in modified Hank's buffer overnight, then washed three times.
188 Neutrophils (2×10^5 cells) in 200 µl were added and allowed to adhere/spread for 60 min at 37°C
189 in CO₂ thermostat, then fixed with 2% paraformaldehyde for 5 min at 37°C, followed by washing
190 twice with PBS. For blocking experiments, cells were preincubated with 50 µg/ml anti-CD11b
191 (clone: ICRF44; Biolegend, San Diego, CA) or with control mouse IgG1 mAb (in house) for 20

192 min at 4°C. The adhered cells were stained with Phalloidin Alexa-488 (Molecular Probes-
193 Invitrogen; 1:100 in 0.1% Triton X-100) for 5 min at 37°C, and then washed four times with PBS.
194 The contact surface of the cells was monitored in Olympus FluoView 500 laser-scanning
195 confocal microscope (excitation: 488 nm). For measuring of the contact zone area we used
196 ImageJ software (<http://rsbweb.nih.gov/ij>) with Analyze Particle tool.

197

198 **2.7. Cell migration assay**

199 Cell migration assays were performed in serum-free RPMI-1640 medium using Costar 24-
200 transwell plates (Corning Life Sciences, Corning, NY) with 3 µm-pore polycarbonate
201 membranes. 50 µg/ml FH, 50 µg/ml HSA and 1 µM fMLF (both from Sigma-Aldrich) as positive
202 control were added to the lower chamber. Neutrophils were stained with 5 µM Cell tracker green
203 (Invitrogen) for 45 min at 37°C. After washing, 10⁶ neutrophils were added to the top chamber
204 for 60 min at 37°C in a CO₂ thermostat, then 25 mM EDTA was added to the lower chamber to
205 release neutrophils adhering to the bottom of the membrane and the bottom of the well. The
206 relative fluorescence intensity of migrated neutrophils was measured using a Fluoroskan Ascent
207 FL (Thermo Scientific, Waltham, MA) microplate reader with excitation and emission filters of
208 495 nm and 515 nm, respectively.

209

210 **2.8. ELISA**

211 To determine the FH concentration in the upper chamber of the transwell system, microtiter
212 plates were coated overnight with 1:1000 dilution of polyclonal goat anti-human FH antibody.
213 After washing with PBS containing 0.05% Tween-20. Supernatants diluted 1:1 with PBS were
214 added to the wells and incubated for 1 h at 22°C. After washing, 1:1000 dilution of a mouse anti-
215 FH mAb (A229; Quidel, San Diego, CA) was added for 1 h at 22°C, followed by a secondary

216 antibody for further 1 h at 22°C. The ELISA was developed using TMB substrate (Kem-En-Tec
217 Diagnostics, Taastrup, Denmark), and the absorbance was measured at 450 nm.

218 IL-8 in the supernatant of activated neutrophils was determined using a commercial
219 ELISA kit (R&D Systems, McKinley Place, MN).

220 Lactoferrin was measured using sandwich ELISA. 4 µg/ml anti-lactoferrin mAb (Hytest,
221 Turku, Finland) was immobilized on microtiter plates at 4°C overnight. After blocking with 5%
222 BSA for 1 h, supernatants of activated cells were added for 1 h at 22°C. Lactoferrin was detected
223 using 100 ng/ml HRP-conjugated anti-lactoferrin Ig (antibodies-online, Aachen, Germany), and
224 TMB substrate.

225

226 **2.9. NET induction by PMA**

227 Wells of 96-well black transparent-bottom plates (Greiner Bio-One, Kremsmünster, Austria)
228 were either left untreated or coated overnight with 50 µg/ml FH in modified Hank's buffer.
229 Neutrophils (10^6 cells) were allowed to adhere to the wells for 30 min at 37°C in CO₂ thermostat.
230 Soluble FH (50 µg/ml) or 100 nM PMA (Sigma-Aldrich) as a positive control was added and
231 after 3 h of incubation in CO₂ thermostat at 37°C, NETs were visualized on adherent neutrophils
232 by addition of 5 µM Sytox Orange nucleic acid stain (Molecular Probes-Invitrogen).

233

234 **2.10. NET induction by fibronectin and β-glucan**

235 96-well black transparent-bottom plates were coated overnight with 6 µg/ml human fibronectin
236 (Fn, from human plasma; Sigma-Aldrich) in TBS (25 mM Tris [pH 7.2], 150 mM NaCl) and/or
237 with 1 mg/ml β-glucan from *S. cerevisiae* (Sigma-Aldrich) in 50 µl. In some experiments, 50
238 µg/ml FH or 50 µg/ml iC3b was immobilized. 10^6 cells were pre-treated on ice with 1 nM fMLF
239 for 20 min, then washed and resuspended in serum free RPMI-1640 medium, and 1 mM Mn²⁺

240 was added to the cells immediately before plating. After 1 h incubation in CO₂ thermostat at
241 37°C, NETs were visualized on adherent neutrophils by adding 5 µM Sytox Orange.

242 In parallel, an adhesion assay was also performed. Neutrophils were stained with 5 µM
243 Cell tracker green CMFDA (Molecular Probes-Invitrogen) for 45 min at 37°C. After washing,
244 10⁶ neutrophils were added to the plates for 1 h. The relative fluorescence intensity of adhered
245 neutrophils was measured using a fluorescence reader with excitation and emission filters of 495
246 nm and 515 nm, respectively.

247

248 **2.11. Immunostaining of MPO and citrullinated histone H4**

249 After NET induction, DNA was labelled with 5 µM Sytox Orange, then the neutrophils were
250 fixed with 3% paraformaldehyde for 10 min at 37°C. The cells were permeabilized in 0.1%
251 Triton X-100 (2 min), washed three times in PBS and then FcR blocking reagent (Miltenyi
252 Biotec, Germany) with 5% BSA was added for 30 min at 37°C. For detection of MPO and
253 citrullinated H4, mouse monoclonal anti-MPO (1:500; Hytest Ltd.) and rabbit polyclonal anti-
254 histone H4 (citrulline 3) (1:500; Merck-Millipore) antibodies were used, followed by the
255 corresponding secondary antibodies (Alexa-647-conjugated goat anti-mouse Ig and Alexa-488-
256 conjugated goat anti-rabbit Ig, both from Molecular Probes-Invitrogen) for 30 min at 22°C.

257 Fluorescence microscopy was carried out on an Olympus FLUOView500 laser-scanning
258 confocal microscope (Hamburg, Germany) equipped with argon ion laser (488 nm) and two He-
259 Ne lasers (with 543 and 632 nm excitation wavelengths, respectively). Typically, fluorescence
260 and DIC images (512x512 pixels) were acquired using a 60x oil-immersion- or 20x objective.
261 Images were processed by ImageJ software (<http://rsbweb.nih.gov/ij>) using the „Image Correlator
262 Plus" colocalization analysis plugin.

263

264 **2.12. Quantification of NETs**

265 The relative fluorescence intensity of extracellular DNA was measured using a Fluoroskan
266 Ascent FL (Thermo Scientific) fluorescent ELISA microplate reader with excitation and emission
267 filters of 543 nm and 592 nm, respectively. Fluorescence in samples labelled with 5 μ M Sytox
268 Orange containing 0.5 mg/ml saponin (Sigma-Aldrich) was taken as maximal signal (100%).
269 Relative fluorescence increase in the examined samples was calculated and referred to as
270 “extracellular DNA (% of max)”.

271

272 **2.13. Detection of reactive oxygen species (ROS)**

273 ROS was measured on PMA- or fibronectin plus β -glucan activated cells in modified Hank’s
274 buffer by adding 5 μ g/ml dihydrorhodamine (DHR) (Sigma-Aldrich) for the last 15 min of 1 h
275 incubation at 37°C. The fluorescence signal of the oxidized DHR was measured in a fluorescence
276 reader with excitation and emission filters of 485 and 538 nm, respectively.

277

278 **2.14. Statistical analysis**

279 Statistical analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad
280 Software, San Diego, California). A *p* value < 0.05 was considered statistically significant.

281

282 3. Results

283

284 3.1. Neutrophil-bound FH retains its cofactor activity and enhances C3b degradation

285 FH when attached via its C-terminal domains to certain host surfaces, such as endothelial cells,
286 erythrocytes and basement membranes, is thought to play an important role in preventing
287 complement-mediated inflammation and cell damage (Ferreira et al., 2009; Ferreira et al., 2006;
288 Jozsi et al., 2007). Therefore, we tested whether FH when bound to neutrophil granulocytes, can
289 exert complement regulatory activity. First, binding of 50 µg/ml FH was analyzed by flow
290 cytometry and microscopy. FH showed strong specific binding to human neutrophils (**Fig. 1A**),
291 in agreement with previous results (Avery and Gordon, 1993; DiScipio et al., 1998; Losse et al.,
292 2010), and suggesting a receptor-mediated binding different from its loose surface attachment via
293 the host surface glycosaminoglycan/sialic acid binding site. Even though the plasma FH
294 concentration is higher, we used this concentration because in contrast to our in vitro system with
295 neutrophils only, blood contains various cell types in different numbers and with different affinity
296 for FH, and also because our previous data showed saturation of receptors on neutrophils by this
297 amount of FH (Losse et al., 2010). Previous results using monoclonal antibodies suggested that
298 the β_2 integrin CR3 is involved in FH binding to neutrophils (DiScipio et al., 1998; Losse et al.,
299 2010). Here, we confirmed this by confocal microscopy, where the calculated positive Pearson's
300 correlation coefficient (0.3 ± 0.007) indicated colocalization between CD11b and FH (**Fig. 1B**).

301 Since FH is the major regulator of the alternative complement pathway, we tested if it is
302 able to facilitate C3b inactivation when bound to CR3 on neutrophils. In the cofactor assay,
303 purified C3b and factor I were incubated with neutrophils, which were either preincubated or not
304 with FH. The cleavage of C3b was analyzed by Western blot. Incubation of C3b with cells alone,
305 in the absence of any added factors I and H, resulted in the cleavage of the C3b α' -chain into

306 fragments with apparent Mw of 68, 46 and 43 kDa (**Fig. 1C, lane 4**), indicating activity of
307 membrane-anchored complement regulators and/or that of FH, which may already be bound in a
308 small amount on the surface of neutrophils purified from blood (Losse et al., 2010). When
309 neutrophils were preincubated with FH, strongly increased C3b degradation was observed: all of
310 the α' -chains were fragmented (**Fig. 1D, lane 7**). These results demonstrated that receptor-bound
311 FH could act as a cofactor for factor I, which proteolytically inactivates C3b.

312

313 **3.2. FH supports neutrophil spreading and migration**

314 Because FH was shown to serve as an adhesion ligand for neutrophils and to induce cell
315 polarization (DiScipio et al., 1998), we tested whether FH influences the spreading of
316 neutrophils. Neutrophils were applied to wells coated with FH and BSA, and neutrophil
317 spreading was monitored by confocal microscopy using fluorescent F-actin probe to measure the
318 contact zone area. Under these experimental conditions, significantly increased spreading was
319 observed on immobilized FH compared with BSA (**Fig. 2A and 2B**). A mAb blocking the ligand
320 binding site on CD11b inhibited spreading on FH, whereas the control mAb had no effect (**Fig.**
321 **2B**).

322 Upon stimulation with immobilized FH, we could observe calcium signal with live cell
323 imaging microscope. The recording was started immediately after the cells were placed into the
324 wells, since as they reached the bottom of the plate an activation stimulus was quickly provided.
325 A small intracellular Ca^{2+} peak occurred within a few minutes in all cases after adhesion to the
326 chamber, and was followed by additional intense Ca^{2+} peak and rapid spreading due to the
327 interaction with FH (**Fig. 3A and Supplementary Video 1**). Changes in intracellular Ca^{2+} level
328 were also quantified (**Fig. 3B**). We did not observe similar effect with immobilized BSA
329 (**Supplementary Video 2**). Freshly isolated neutrophils were also incubated with 50 μ g/ml FH

330 for 1-20 min. Soluble FH did not induce Ca^{2+} signals in neutrophils, in contrast to ionomycin,
331 which was used as a positive control (**Fig. 3C**).

332 Previous data suggested that FH may also support cell migration, as reported for monocytes
333 and also for neutrophils when exposed to FH-coated *Candida albicans* yeasts (Losse et al., 2010;
334 Nabil et al., 1997). Therefore, we tested whether FH modulates the migratory capacity of
335 neutrophils. The cell migration assays were performed in transwell plates with 3 μm -pore
336 polycarbonate membranes. The measured fluorescence of migrated cells induced by 1 μM fMLF
337 as positive control was set as 100%. Addition of FH to the lower chamber of transwells caused
338 significantly increased neutrophil migration compared with medium control, ~65% of that
339 induced by fMLF (**Fig. 4A**). We also tested whether FH added to the lower chamber passes to the
340 upper chamber. FH could be detected in all cases in the upper chamber by ELISA, confirming the
341 formation of a FH concentration gradient (**Fig. 4B**).

342

343 **3.3. Immobilized FH enhances IL-8 release from neutrophils**

344 Because IL-8 is a known migratory chemokine for neutrophils, we tested if FH is able to induce
345 IL-8 production by neutrophils. Neutrophils were stimulated either with soluble or immobilized
346 FH in FCS-free RPMI-1640 medium for 24 h, then the amount of IL-8 in the supernatants was
347 measured by ELISA. Under these circumstances immobilized FH significantly enhanced IL-8
348 production, while for soluble FH a similar effect was not observed (**Fig. 5**). The effect was
349 specific to FH since immobilized fibronectin did not induce enhanced IL-8 release from
350 neutrophils under the same conditions (data not shown).

351

352 **3.4. NET formation and ROS production induced by PMA and by fibronectin plus fungal** 353 **β -glucan is inhibited by FH**

354 Neutrophils are rapidly recruited in tissues during infections and have a wide repertoire of killing
355 mechanisms to eliminate pathogens, including respiratory burst and NET formation (Brinkmann
356 et al., 2004; Kirchner et al., 2012; Nathan, 2006). Because little is known about how complement
357 modulates NET production, we asked the question whether FH is able to influence the generation
358 of NETs.

359 First, we used a PMA-induced NET formation model (Keshari et al., 2013; Parker et al.,
360 2012), where after 3 h of treatment ~60% of the total DNA was detectable extracellularly (**Fig.**
361 **6A**). Under the same conditions, soluble or immobilized FH alone had no effect on NET
362 production (**Fig. 6B and 6C**). However, when applied together with PMA, immobilized but not
363 soluble FH could significantly decrease the amount of extracellular DNA (**Fig. 6C**). Because FH
364 is known to bind to DNA (Leffler et al., 2010), we tested if FH binding affects the staining of the
365 DNA with Sytox Orange. FH up to 50 µg/ml did not affect the fluorescence signal (data not
366 shown). The formation of NETs was confirmed by confocal microscopic analysis, which showed
367 that the DNA was indeed associated with myeloperoxidase and citrullinated histone H4 (**Figure**
368 **S1**). Because NET generation is usually linked to the production of ROS (Fuchs et al., 2007;
369 Kirchner et al., 2012; Parker et al., 2012), we analyzed the generation of ROS under the same
370 conditions as above. Again, PMA-induced ROS generation by neutrophils was significantly
371 reduced by immobilized but not by soluble FH, and FH alone did not induce ROS under these
372 conditions (**Fig. 6D**).

373 An extracellular matrix-based model was also used, where human fibronectin and β-glucan, a
374 major component of fungal cell wall, together induced NET release, as described by Byrd *et al.*
375 (Byrd et al., 2013). Neutrophils were primed with 1 nM fMLF in the presence of 1 mM Mn²⁺ and
376 showed rapid homotypic cell aggregation upon NET formation (**Fig. 7A**), as described (Byrd et

377 al., 2013). In this system, FH also inhibited NET formation induced by fibronectin plus fungal β -
378 glucan (**Fig. 7A and 7B**).

379 As a control, we used iC3b as additional complement ligand of CR3. iC3b is a proteolytically
380 inactivated product of the complement C3 cleavage fragment C3b, which opsonizes pathogens
381 and enhances the cell responses against them. Under our experimental conditions, iC3b did not
382 significantly alter NET generation, thus supporting a specific effect of FH (**Fig. 7B**). We also
383 tested if differences between cell adhesion properties to the applied coats caused the observed
384 effects on NET formation. Neutrophils were loaded with Cell Tracker Green and the percentage
385 of the bound cells was determined compared to the total cell number. As we measured similar
386 cell adherence rates, it can be excluded that the observed differences in NETs are due to altered
387 adhesion, and support the specific inhibitory effect of FH on the release of NETs (**Fig. 7C**).

388 Similar to the previously observed inhibitory effects of FH on ROS induced by PMA (**Fig. 6**),
389 FH inhibited ROS production in neutrophils stimulated by fibronectin plus β -glucan (**Fig. 7D**). In
390 these experiments, iC3b did not influence ROS production. In addition, we measured lactoferrin
391 production by neutrophils in parallel, which was not modulated significantly by either FH or
392 iC3b under these conditions (**Fig. 7E**).

393

394 4. Discussion

395 FH inhibits the alternative complement pathway in body fluids and also protects self-tissues
396 against complement attack and complement-mediated inflammation. FH can loosely attach to
397 host surfaces, such as endothelial cells, erythrocytes and basement membranes, via
398 glycosaminoglycans and sialic acids, and this binding is enhanced if C3 fragments are also
399 deposited on the surface due to complement activation (Blaum et al., 2015; Ferreira et al., 2009;
400 Jozsi et al., 2007; Kajander et al., 2011). In addition, recruitment of host FH is a common
401 complement/immune evasion strategy of several pathogenic microbes. In some cases, such as for
402 *Neisseria meningitidis*, FH binding is of major importance to avoid complement-mediated lysis;
403 in most cases, however, microbes exploit host complement regulators to evade
404 opsonophagocytosis (Lambris et al., 2008; Ram et al., 1999; Schneider et al., 2006). There is also
405 evidence for FH-mediated adhesion of microbes to host cells, including neutrophils (Losse et al.,
406 2010; Agarwal et al., 2010a; Agarwal et al., 2010b).

407 In the case of neutrophil granulocytes, the binding of FH was shown to be mediated via the
408 CR3 complement receptor (DiScipio et al., 1998; Losse et al., 2010; Agarwal et al., 2010b). As
409 demonstrated here, despite the specific receptor-ligand interaction, FH retains its cofactor activity
410 (**Fig. 1**); moreover, through the direct effects on neutrophils, it is also able to modulate neutrophil
411 activation and antimicrobial responses.

412 Previous data provided evidence that FH has a specific receptor on neutrophil granulocytes
413 (Avery and Gordon, 1993; DiScipio et al., 1998). DiScipio *et al.* identified CR3 (CD11b/CD18,
414 $\alpha_M\beta_2$) as the main FH receptor on neutrophils (DiScipio et al., 1998), which was confirmed by
415 our group using specific antibodies against the CD11b (clone ICRF44) and CD18 (clone L130)
416 chains that inhibited FH binding (Losse et al., 2010). In our current study we demonstrated
417 colocalization between CD11b (with mAb clone M1/70.15) and FH by confocal microscopy (**Fig.**

418 2). We could not detect similar colocalization with CD18, because depending on the order of
419 labeling only CD18 (clone IB4) or FH could be detected on the cell surface (data not shown),
420 likely due to strong competition between the anti-CD18 mAb and FH for binding. Previously we
421 showed that anti-CD18 almost completely blocked FH binding to neutrophils (Losse et al., 2010).
422 Based on these data, CD18 may have a major role in FH binding. These results, however, do not
423 exclude the existence of additional FH receptors on the cells.

424 FH was described as an adhesion ligand for neutrophils (DiScipio et al., 1998); moreover, as
425 we reported previously, *C. albicans* covered with FH could more efficiently induce migration and
426 become adhered to and phagocytosed by neutrophils than the fungal cells alone (Losse et al.,
427 2010). Similarly, it was shown that FH enhanced the interaction of pneumococci with neutrophils
428 through CR3 (Agarwal et al., 2010b). In addition, FH was described as a chemotactic factor for
429 monocytes (Nabil et al., 1997). Therefore, we studied whether FH can directly, i.e. without a
430 pathogen, affect neutrophil activation, migration and spreading. Soluble FH was indeed able to
431 support neutrophil migration in a transwell assay (**Fig. 4**). While FH is produced in the liver and
432 circulates at relatively high concentration, extrahepatic sources of local FH production are also
433 known. Myeloid cells in tissues and endothelial cells can produce FH upon inflammatory stimuli
434 (Brooimans et al., 1990; Li et al., 2011; Whaley, 1980), which may contribute to generating a
435 local FH gradient and thus promote recruitment of neutrophils.

436 Apparently, the soluble and immobilized forms of FH do not provide the same information to
437 the cells. In our experiments, only immobilized but not soluble FH could trigger calcium
438 response and spreading (**Fig. 2 and 3**), and could induce IL-8 production in neutrophils (**Fig. 5**).
439 IL-8 is a potent proinflammatory chemokine and has a key role in the recruitment and activation
440 of neutrophils (Mantovani et al., 2011). Therefore, presumably an activation process occurs when
441 neutrophils come into contact with FH that is bound to surfaces, which may enhance cell entry to

442 the given area. No effect of soluble FH on neutrophil activation was observed, except for the
443 migration in the case of FH gradient. This is an important observation because of the relatively
444 high average plasma concentration (~250 µg/ml) of FH. Thus, the continuously circulating FH in
445 the body fluids does not stimulate neutrophils; however, when deposited on a pathogen surface
446 (as shown for the fungal pathogen *C. albicans* in vitro) or in the tissues, it may affect the
447 recruitment and activation of these inflammatory cells. This, however, needs to be further studied
448 for in vivo relevance. It should also be noted that integrin receptors can sense differences
449 between soluble and immobilized ligands (Ganpule et al., 1997; Schurpf and Springer, 2011),
450 further supporting the observations that CR3, and probably CR4 (CD11c/CD18), another integrin
451 sharing the β_2 chain but which is expressed at low amount on neutrophils, are specific FH
452 receptors (Losse et al., 2010; Svoboda et al., 2015).

453 Neutrophils are not simply effective and fast killer/effector cells, but depending on the size
454 and nature of the pathogen they deploy different antimicrobial responses. They can selectively
455 release NETs in response to fungal hyphae and pathogens, which are too large to be
456 phagocytosed (Branzk et al., 2014; Byrd et al., 2013; Svobodova et al., 2012). These DNA-based,
457 web-like structures have effective trapping function and are able to prevent pathogen expansion
458 and dissemination. Moreover, neutrophils can eliminate pathogens extracellularly, by releasing
459 antimicrobial peptides, enzymes and reactive oxygen and nitrogen species concentrated to the
460 target area and partly in NETs (Brinkmann et al., 2004; Fuchs et al., 2007; Guimaraes-Costa et
461 al., 2009; Menten-Dedoyart et al., 2012). Extracellular histones exert bactericidal effects (Allam
462 et al., 2014; Brinkmann et al., 2004), but are also toxic to host cells, such as endothelial cells
463 (Allam et al., 2014). Although Byrd *et al.* found that complement does not have an essential role
464 in NET production, since using autologous human serum in their model system did not alter the
465 NETting of the cells when compared to the cells under serum free conditions (Byrd et al., 2013),

466 there is also evidence for a modulatory role of complement. Pre-activated neutrophils were
467 shown to release NETs upon C5a stimulation (Martinelli et al., 2004; Yousefi et al., 2009).
468 Therefore, we analyzed whether NET release could be modulated by FH. First we used PMA as a
469 general cell activator agent (DeChatelet et al., 1976; Esaguy et al., 1991), for which effective
470 NET inducing ability has been described (Brinkmann et al., 2004; Keshari et al., 2013; Parker et
471 al., 2012). In this model system, the soluble and immobilized forms of FH alone did not induce
472 NETs. Only immobilized FH could modulate NETosis and significantly decreased the PMA-
473 induced NET- and ROS release (**Fig. 6**). Several publications indicated that NETosis is strongly
474 dependent on ROS generation (Fuchs et al., 2007; Keshari et al., 2013; Kirchner et al., 2012),
475 although a ROS-independent process was also described (Byrd et al., 2013; Pilszczek et al., 2010).
476 While the underlying mechanisms of NET release are not yet fully understood, we presume that
477 the decreased NET formation is linked to the decreased ROS production caused by FH in our in
478 vitro NET model.

479 In addition, an extracellular matrix-based model was used to investigate NET production,
480 where a hyphal infection can be mimicked with immobilized fungal β -glucan (Byrd et al., 2013).
481 A cross-regulatory relationship between β_1 and β_2 integrins has been described, in which the ratio
482 of fibronectin to β -glucan determines the cellular responses. This regulatory mechanism allows
483 superoxid anion production only when neutrophils formed strong contact with fungal hyphae
484 (Lavigne et al., 2006; Lavigne et al., 2007). In our experimental set-up immobilized fibronectin
485 plus β -glucan could effectively induce NET and ROS production. While Byrd *et al.* reported that
486 fibronectin plus β -glucan induced NET formation is a ROS-independent process and they could
487 not detect ROS production upon this stimulus (Byrd et al., 2013), in our experiments there was
488 detectable ROS production. This difference may be due to the different β -glucan preparations and
489 the different cells to surface ratio employed. In addition, instead of ferricytochrome c we used

490 DHR as a ROS detecting probe, which detects both extracellular and intracellular reactive species
491 with higher response ability and less dependency on the applied buffer (Freitas et al., 2009). In
492 our model we also found that immobilized FH had an inhibitory effect on NET release and ROS
493 production (**Fig. 7**). The NET response to β -glucan plus fibronectin was found to be dependent
494 on CR3 (Byrd et al., 2013), and both FH and iC3b bind also to CR3. iC3b, in contrast to FH, did
495 not inhibit NET release induced by fibronectin plus β -glucan. A direct competition between FH
496 and β -glucan for binding sites on CR3 cannot be excluded; however, FH also strongly inhibited
497 PMA-induced NETosis. While FH reduced ROS production, it did not significantly affect
498 lactoferrin release, thus bactericidal ability of neutrophils in general is not inhibited by FH. It is
499 also possible, however, that some of the released lactoferrin is sequestered by NETs.

500 Taken together these data provide evidence that FH ensures self protection not only by
501 limiting complement activation, but also by directly mediating cellular responses. On the one
502 hand, FH can promote neutrophil recruitment (**Figs. 4 and 5**) and may enhance antimicrobial
503 responses and phagocytosis (Losse et al., 2010). On the other hand, FH could reduce host damage
504 caused by an inflammatory environment through the inhibition of NET and ROS production.
505 Prolonged presence or enhanced amounts of NETs may be linked to inflammatory and
506 autoimmune diseases, e.g. by providing autoantigens such as dsDNA. Furthermore, extracellular
507 histone may cause cytotoxicity. By inhibiting NET and ROS, FH may limit such adverse
508 reactions. It is tempting to speculate that in FH-associated diseases, such as the kidney disease
509 atypical hemolytic uremic syndrome, hereditary or acquired functional FH deficiency may
510 contribute to local inflammation, NET-mediated complement activation (Leffler et al., 2012;
511 Wang et al., 2015), endothelial damage and thrombus formation, in addition to impairment in
512 complement regulation. The results also raise the possibility that bound FH may be exploited by
513 pathogenic microbes not only for complement evasion, which is a well-documented virulence

514 feature (Lambris et al., 2008), but for NET evasion, too. FH-associated anti-inflammatory effect
515 was demonstrated previously on macrophages, where FH contributed to the non-inflammatory
516 clearance of apoptotic and necrotic cells by inhibiting the pro-inflammatory cytokine production
517 of phagocytosing macrophages (Mihlan et al., 2009).

518 In summary, these data indicate that FH has diverse effects on neutrophil functions. While it
519 can support the recruitment of neutrophils via promoting migration and enhancing IL-8 release,
520 depending on the stimulus context FH could also exert anti-inflammatory effects and influence
521 local inflammatory and antimicrobial reactions as well as tissue damage by modulating NET
522 formation.

523

524

525 **Acknowledgements**

526 We thank the healthy volunteers for blood donation. This work was financially supported in part
527 by the “Lendület” Program of the Hungarian Academy of Sciences (grant LP2012-43 to M.J.), by
528 MedInProt, and also by the European Union and co-financed by the European Social Fund (grant
529 agreement no. TÁMOP 4.2.1./B-09/1/KMR-2010-0003).

530

531 **References**

- 532 Adler J. and Parmryd I. (2010) Quantifying colocalization by correlation: the Pearson correlation
533 coefficient is superior to the Mander's overlap coefficient. *Cytometry A* **77**, 733-42.
- 534 Agarwal S., Ram S., Ngampasutadol J., Gulati S., Zipfel P. F., Rice P. A. (2010a) Factor H
535 facilitates adherence of *Neisseria gonorrhoeae* to complement receptor 3 on eukaryotic
536 cells. *J Immunol* **185**, 4344-53.
- 537 Agarwal V., Asmat T. M., Luo S., Jensch I., Zipfel P. F., Hammerschmidt S. (2010b)
538 Complement regulator Factor H mediates a two-step uptake of *Streptococcus pneumoniae*
539 by human cells. *J Biol Chem* **285**, 23486-95.
- 540 Allam R., Kumar S. V., Darisipudi M. N. and Anders H. J. (2014) Extracellular histones in tissue
541 injury and inflammation. *J Mol Med (Berl)* **92**, 465-72.

542 Avery V. M. and Gordon D. L. (1993) Characterization of factor H binding to human
543 polymorphonuclear leukocytes. *J Immunol* **151**, 5545-53.

544 Behnen M., Leschczyk C., Moller S., Batel T., Klinger M., Solbach W. and Laskay T. (2014)
545 Immobilized immune complexes induce neutrophil extracellular trap release by human
546 neutrophil granulocytes via FcγRIIIB and Mac-1. *J Immunol* **193**, 1954-65.

547 Blaum B. S., Hannan J. P., Herbert A. P., Kavanagh D., Uhrin D. and Stehle T. (2015) Structural
548 basis for sialic acid-mediated self-recognition by complement factor H. *Nat Chem Biol*
549 **11**, 77-82.

550 Branzk N., Lubojemska A., Hardison S. E., Wang Q., Gutierrez M. G., Brown G. D. and
551 Papayannopoulos V. (2014) Neutrophils sense microbe size and selectively release
552 neutrophil extracellular traps in response to large pathogens. *Nat Immunol* **15**, 1017-25.

553 Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D. S., Weinrauch Y.
554 and Zychlinsky A. (2004) Neutrophil extracellular traps kill bacteria. *Science* **303**, 1532-
555 5.

556 Brooimans R. A., van der Ark A. A., Buurman W. A., van Es L. A. and Daha M. R. (1990)
557 Differential regulation of complement factor H and C3 production in human umbilical
558 vein endothelial cells by IFN-γ and IL-1. *J Immunol* **144**, 3835-40.

559 Byrd A. S., O'Brien X. M., Johnson C. M., Lavigne L. M. and Reichner J. S. (2013) An
560 extracellular matrix-based mechanism of rapid neutrophil extracellular trap formation in
561 response to *Candida albicans*. *J Immunol* **190**, 4136-48.

562 DeChatelet L. R., Shirley P. S. and Johnston R. B., Jr. (1976) Effect of phorbol myristate acetate
563 on the oxidative metabolism of human polymorphonuclear leukocytes. *Blood* **47**, 545-54.

564 DiScipio R. G., Daffern P. J., Schraufstatter I. U. and Sriramarao P. (1998) Human
565 polymorphonuclear leukocytes adhere to complement factor H through an interaction that
566 involves αMβ2 (CD11b/CD18). *J Immunol* **160**, 4057-66.

567 Erdei A. and Sim R. B. (1987) Complement factor H-binding protein of Raji cells and tonsil B
568 lymphocytes. *Biochem J* **246**, 149-56.

569 Esaguy N., Aguas A. P., Vilanova M. and Silva M. T. (1991) Activation of human neutrophils by
570 phorbol ester decreases the cytoplasm compactness and the lactoferrin content of the
571 granulocytes. *J Leukoc Biol* **50**, 444-52.

572 Farrera C. and Fadeel B. (2013) Macrophage clearance of neutrophil extracellular traps is a silent
573 process. *J Immunol* **191**, 2647-56.

574 Ferreira V. P., Herbert A. P., Cortes C., McKee K. A., Blaum B. S., Esswein S. T., Uhrin D.,
575 Barlow P. N., Pangburn M. K. and Kavanagh D. (2009) The binding of factor H to a
576 complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic
577 uremic syndrome. *J Immunol* **182**, 7009-18.

578 Ferreira V. P., Herbert A. P., Hocking H. G., Barlow P. N. and Pangburn M. K. (2006) Critical
579 role of the C-terminal domains of factor H in regulating complement activation at cell
580 surfaces. *J Immunol* **177**, 6308-16.

581 Ferreira V. P., Pangburn M. K. and Cortes C. (2010) Complement control protein factor H: the
582 good, the bad, and the inadequate. *Mol Immunol* **47**, 2187-97.

583 Freitas M., Porto G., Lima J. L. and Fernandes E. (2009) Optimization of experimental settings
584 for the analysis of human neutrophils oxidative burst in vitro. *Talanta* **78**, 1476-83.

585 Fuchs T. A., Abed U., Goosmann C., Hurwitz R., Schulze I., Wahn V., Weinrauch Y.,
586 Brinkmann V. and Zychlinsky A. (2007) Novel cell death program leads to neutrophil
587 extracellular traps. *J Cell Biol* **176**, 231-41.

588 Ganpule G., Knorr R., Miller J. M., Carron C. P. and Dustin M. L. (1997) Low affinity of cell
589 surface lymphocyte function-associated antigen-1 (LFA-1) generates selectivity for cell-
590 cell interactions. *J Immunol* **159**, 2685-92.

591 Guimaraes-Costa A. B., Nascimento M. T., Froment G. S., Soares R. P., Morgado F. N.,
592 Conceicao-Silva F. and Saraiva E. M. (2009) Leishmania amazonensis promastigotes
593 induce and are killed by neutrophil extracellular traps. *Proc Natl Acad Sci U S A* **106**,
594 6748-53.

595 Hartung H. P., Hadding U., Bitter-Suermann D. and Gemsa D. (1984) Release of prostaglandin E
596 and thromboxane from macrophages by stimulation with factor H. *Clin Exp Immunol* **56**,
597 453-8.

598 Iferroudjene D., Schouft M. T., Lemercier C., Gilbert D. and Fontaine M. (1991) Evidence for an
599 active hydrophobic form of factor H that is able to induce secretion of interleukin 1-beta
600 or by human monocytes. *Eur J Immunol* **21**, 967-72.

601 Jozsi M., Oppermann M., Lambris J. D. and Zipfel P. F. (2007) The C-terminus of complement
602 factor H is essential for host cell protection. *Mol Immunol* **44**, 2697-706.

603 Kajander T., Lehtinen M. J., Hyvarinen S., Bhattacharjee A., Leung E., Isenman D. E., Meri S.,
604 Goldman A. and Jokiranta T. S. (2011) Dual interaction of factor H with C3d and
605 glycosaminoglycans in host-nonhost discrimination by complement. *Proc Natl Acad Sci*
606 *U S A* **108**, 2897-902.

607 Kang Y. H., Urban B. C., Sim R. B. and Kishore U. (2012) Human complement Factor H
608 modulates C1q-mediated phagocytosis of apoptotic cells. *Immunobiology* **217**, 455-64.

609 Keshari R. S., Verma A., Barthwal M. K. and Dikshit M. (2013) Reactive oxygen species-
610 induced activation of ERK and p38 MAPK mediates PMA-induced NETs release from
611 human neutrophils. *J Cell Biochem* **114**, 532-40.

612 Kirchner T., Moller S., Klingner M., Solbach W., Laskay T. and Behnen M. (2012) The impact of
613 various reactive oxygen species on the formation of neutrophil extracellular traps.
614 *Mediators Inflamm* **2012**, 849136.

615 Kolaczowska E. and Kubes P. (2013) Neutrophil recruitment and function in health and
616 inflammation. *Nat Rev Immunol* **13**, 159-75.

617 Kopp A., Hebecker M., Svobodova E. and Jozsi M. (2012) Factor h: a complement regulator in
618 health and disease, and a mediator of cellular interactions. *Biomolecules* **2**, 46-75.

619 Lambris J. D., Dobson N. J. and Ross G. D. (1980) Release of endogenous C3b inactivator from
620 lymphocytes in response to triggering membrane receptors for beta 1H globulin. *J Exp*
621 *Med* **152**, 1625-44.

622 Lambris J. D., Ricklin D. and Geisbrecht B. V. (2008) Complement evasion by human
623 pathogens. *Nat Rev Microbiol* **6**, 132-42.

624 Lavigne L. M., Albina J. E. and Reichner J. S. (2006) Beta-glucan is a fungal determinant for
625 adhesion-dependent human neutrophil functions. *J Immunol* **177**, 8667-75.

626 Lavigne L. M., O'Brien X. M., Kim M., Janowski J. W., Albina J. E. and Reichner J. S. (2007)
627 Integrin engagement mediates the human polymorphonuclear leukocyte response to a
628 fungal pathogen-associated molecular pattern. *J Immunol* **178**, 7276-82.

629 Leffler J., Gullstrand B., Jonsen A., Nilsson J. A., Martin M., Blom A. M. and Bengtsson A. A.
630 (2013) Degradation of neutrophil extracellular traps co-varies with disease activity in
631 patients with systemic lupus erythematosus. *Arthritis Res Ther* **15**, R84.

632 Leffler J., Herbert A. P., Norstrom E., Schmidt C. Q., Barlow P. N., Blom A. M. and Martin M.
633 (2010) Annexin-II, DNA, and histones serve as factor H ligands on the surface of
634 apoptotic cells. *J Biol Chem* **285**, 3766-76.

635 Leffler J., Martin M., Gullstrand B., Tyden H., Lood C., Truedsson L., Bengtsson A. A. and
636 Blom A. M. (2012) Neutrophil extracellular traps that are not degraded in systemic lupus
637 erythematosus activate complement exacerbating the disease. *J Immunol* **188**, 3522-31.

638 Li K., Fazekasova H., Wang N., Sagoo P., Peng Q., Khamri W., Gomes C., Sacks S. H.,
639 Lombardi G. and Zhou W. (2011) Expression of complement components, receptors and
640 regulators by human dendritic cells. *Mol Immunol* **48**, 1121-7.

641 Losse J., Svobodova E., Heyken A., Hube B., Zipfel P. F. and Jozsi M. (2011) Role of pH-
642 regulated antigen 1 of *Candida albicans* in the fungal recognition and antifungal response
643 of human neutrophils. *Mol Immunol* **48**, 2135-43.

644 Losse J., Zipfel P. F. and Jozsi M. (2010) Factor H and factor H-related protein 1 bind to human
645 neutrophils via complement receptor 3, mediate attachment to *Candida albicans*, and
646 enhance neutrophil antimicrobial activity. *J Immunol* **184**, 912-21.

647 Mantovani A., Cassatella M. A., Costantini C. and Jaillon S. (2011) Neutrophils in the activation
648 and regulation of innate and adaptive immunity. *Nat Rev Immunol* **11**, 519-31.

649 Martinelli S., Urosevic M., Daryadel A., Oberholzer P. A., Baumann C., Fey M. F., Dummer R.,
650 Simon H. U. and Yousefi S. (2004) Induction of genes mediating interferon-dependent
651 extracellular trap formation during neutrophil differentiation. *J Biol Chem* **279**, 44123-32.

652 Menten-Dedoyart C., Faccinetto C., Golovchenko M., Dupiereux I., Van Lerberghe P. B., Dubois
653 S., Desmet C., Elmoualij B., Baron F., Rudenko N., Oury C., Heinen E. and Couvreur B.
654 (2012) Neutrophil extracellular traps entrap and kill *Borrelia burgdorferi sensu stricto*
655 spirochetes and are not affected by *Ixodes ricinus* tick saliva. *J Immunol* **189**, 5393-401.

656 Mihlan M., Stippa S., Jozsi M. and Zipfel P. F. (2009) Monomeric CRP contributes to
657 complement control in fluid phase and on cellular surfaces and increases phagocytosis by
658 recruiting factor H. *Cell Death Differ* **16**, 1630-40.

659 Mocsai A. (2013) Diverse novel functions of neutrophils in immunity, inflammation, and beyond.
660 *J Exp Med* **210**, 1283-99.

661 Nabil K., Rihn B., Jaurand M. C., Vignaud J. M., Ripoche J., Martinet Y. and Martinet N. (1997)
662 Identification of human complement factor H as a chemotactic protein for monocytes.
663 *Biochem J* **326 (Pt 2)**, 377-83.

664 Nathan C. (2006) Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* **6**,
665 173-82.

666 Parker H., Dragunow M., Hampton M. B., Kettle A. J. and Winterbourn C. C. (2012)
667 Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap
668 formation differ depending on the stimulus. *J Leukoc Biol* **92**, 841-9.

669 Pilszczek F. H., Salina D., Poon K. K., Fahey C., Yipp B. G., Sibley C. D., Robbins S. M., Green
670 F. H., Surette M. G., Sugai M., Bowden M. G., Hussain M., Zhang K. and Kubes P.
671 (2010) A novel mechanism of rapid nuclear neutrophil extracellular trap formation in
672 response to *Staphylococcus aureus*. *J Immunol* **185**, 7413-25.

673 Ram S., Mackinnon F. G., Gulati S., McQuillen D. P., Vogel U., Frosch M., Elkins C.,
674 Guttormsen H. K., Wetzler L. M., Oppermann M., Pangburn M.K. and Rice P. A. (1999)
675 The contrasting mechanisms of serum resistance of *Neisseria gonorrhoeae* and group B
676 *Neisseria meningitidis*. *Mol Immunol* **36**, 915-28.

677 Remijsen Q., Kuijpers T. W., Wirawan E., Lippens S., Vandenabeele P. and Vanden Berghe T.
678 (2011) Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death
679 modality. *Cell Death Differ* **18**, 581-8.

680 Ricklin D., Hajishengallis G., Yang K. and Lambris J. D. (2010) Complement: a key system for
681 immune surveillance and homeostasis. *Nat Immunol* **11**, 785-97.

682 Rodriguez de Cordoba S., Esparza-Gordillo J., Goicoechea de Jorge E., Lopez-Trascasa M. and
683 Sanchez-Corral P. (2004) The human complement factor H: functional roles, genetic
684 variations and disease associations. *Mol Immunol* **41**, 355-67.

685 Ross G. D., Cain J. A., Myones B. L., Newman S. L. and Lachmann P. J. (1987) Specificity of
686 membrane complement receptor type three (CR3) for beta-glucans. *Complement* **4**, 61-74.

687 Saffarzadeh M. and Preissner K. T. (2013) Fighting against the dark side of neutrophil
688 extracellular traps in disease: manoeuvres for host protection. *Curr Opin Hematol* **20**, 3-9.

689 Schneider M. C., Exley R. M., Chan H., Feavers I., Kang Y. H., Sim R. B. and Tang CM. (2006)
690 Functional significance of factor H binding to *Neisseria meningitidis*. *J Immunol* **176**,
691 7566-75.

692 Schurpf T. and Springer T. A. (2011) Regulation of integrin affinity on cell surfaces. *Embo J* **30**,
693 4712-27.

694 Sur Chowdhury C., Giaglis S., Walker U. A., Buser A., Hahn S. and Hasler P. (2014) Enhanced
695 neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying
696 signal transduction pathways and potential diagnostic utility. *Arthritis Res Ther* **16**, R122.

697 Svoboda E., Schneider A. E., Sandor N., Lermann U., Staib P., Kremlitzka M., Bajtay Z., Barz
698 D., Erdei A. and Jozsi M. (2015) Secreted aspartic protease 2 of *Candida albicans*
699 inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4
700 (CD11c/CD18). *Immunol Lett* **168**, 13-21.

701 Svobodova E., Staib P., Losse J., Hennicke F., Barz D. and Jozsi M. (2012) Differential
702 interaction of the two related fungal species *Candida albicans* and *Candida dubliniensis*
703 with human neutrophils. *J Immunol* **189**, 2502-11.

704 Tsokos G. C., Inghirami G., Tsoukas C. D., Balow J. E. and Lambris J. D. (1985) Regulation of
705 immunoglobulin secretion by factor H of human complement. *Immunology* **55**, 419-26.

706 Urban C. F., Reichard U., Brinkmann V. and Zychlinsky A. (2006) Neutrophil extracellular traps
707 capture and kill *Candida albicans* yeast and hyphal forms. *Cell Microbiol* **8**, 668-76.

708 van Bruggen R., Drewniak A., Jansen M., van Houdt M., Roos D., Chapel H., Verhoeven A. J.
709 and Kuijpers T. W. (2009) Complement receptor 3, not Dectin-1, is the major receptor on
710 human neutrophils for beta-glucan-bearing particles. *Mol Immunol* **47**, 575-81.

711 Vaziri-Sani F., Hellwege J., Zipfel P. F., Sjöholm A. G., Iancu R. and Karpman D. (2005) Factor
712 H binds to washed human platelets. *J Thromb Haemost* **3**, 154-62.

713 Wang H., Wang C., Zhao M. H. and Chen M. (2015) Neutrophil extracellular traps can activate
714 alternative complement pathways. *Clin Exp Immunol* **181**, 518-27.

715 Whaley K. (1980) Biosynthesis of the complement components and the regulatory proteins of the
716 alternative complement pathway by human peripheral blood monocytes. *J Exp Med* **151**,
717 501-16.

718 Yousefi S., Mihalache C., Kozłowski E., Schmid I. and Simon H. U. (2009) Viable neutrophils
719 release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ* **16**,
720 1438-44.

721

722

723

724

725 **Figure legends**

726

727 **Fig. 1. CR3-bound FH on neutrophils retains its cofactor activity.**

728 **(A)** Neutrophils were incubated with 50 $\mu\text{g/ml}$ FH in modified Hank's buffer, and bound FH was
729 detected by flow cytometry. One representative histogram out of three independent experiments
730 is shown. **(B)** Representative confocal images show binding of FH to the cell surface of
731 neutrophils (green: FH, red: CD11b, yellow dots represent highly colocalized FH and CD11b).
732 During a colocalization analysis a Pearson's correlation coefficient was calculated from ≥ 100
733 cells /sample. **(C)** In a cellular cofactor assay, neutrophils preincubated or not with 10 $\mu\text{g/ml}$ FH,
734 were incubated with C3b and factor I. Cell supernatants were separated on 10% SDS-PAGE gel
735 under reducing conditions and analyzed by immunoblotting using anti-C3 antibody to detect C3b
736 fragments. A representative Western blot from three independent experiments is shown. As a
737 positive control, purified FH (10 $\mu\text{g/ml}$), factor I (5 $\mu\text{g/ml}$) and C3b (3 $\mu\text{g/ml}$) have been mixed
738 together in PBS, without cells (lane 2).

739

740 **Fig. 2. FH supports neutrophil spreading.**

741 **(A)** FH and BSA were immobilized in 50 $\mu\text{g/ml}$ in chambered microplate wells, then neutrophils
742 were added to each well for 60 min at 37°C. The contact surface of the cells was monitored by
743 confocal microscopy using Phalloidin-Alexa488 as an F-actin probe. Original scale bars, 10 μm .

744 **(B)** FH was immobilized as in (A), and in certain chambers preincubated with 50 $\mu\text{g/ml}$ anti-
745 CD11b (aCD11b) or control mouse IgG1 (mIgG1) antibodies. The contact zone areas were
746 quantified using ImageJ software from 100 cells in each experiment. Error bars represent SEM
747 calculated from three independent experiments performed with neutrophils from different donors.

748 *** $P < 0.001$, one-way ANOVA. ns, not significant.

749

750 **Fig. 3. Effect of FH on the calcium response of human neutrophils.**

751 (A) Representative confocal images from three independent experiments show neutrophil
752 spreading upon exposure to immobilized FH and the fluorescence intensity of Fluo-4 calcium
753 indicator during this process at different time points. (B) Representative single cell calcium
754 response belonging to the above presented images. Mean fluorescence intensities were
755 normalized to DIC intensities to avoid out of focus intensity alteration effects. (C) Fluo-4-AM-
756 loaded neutrophils were investigated by flow cytometry for their Ca²⁺ response to 50 µg/ml
757 soluble FH. The maximal response of cells to the Ca²⁺ ionophore ionomycin is shown as a
758 positive control. Data are mean ± SD from three independent measurements.

759

760 **Fig. 4. FH supports neutrophil migration.**

761 (A) FH was added to the lower well and the cell migration rate was measured by adding Cell
762 Tracker Green loaded neutrophils to the upper well of a transwell system. The cell number was
763 quantified by plate fluorimeter, as described in Materials and methods. Migration induced by 1
764 µM fMLF was set to 100%. Error bars represent SEM calculated from 16 independent
765 experiments. **P* < 0.05, one-way ANOVA. (B) ELISA was used to determine the amount of FH,
766 added to the lower chamber, in the upper chamber of the transwell system during the experiment
767 described in (A). Data are mean + SEM from seven experiments. ****P* < 0.001, one-way
768 ANOVA.

769

770 **Fig. 5. FH enhances IL-8 release from neutrophils.**

771 Neutrophil supernatants were collected after 24 h stimulation with 50 $\mu\text{g/ml}$ immobilized or
772 soluble FH, and the IL-8 content was determined by a commercial ELISA kit. Data are means \pm
773 SEM from five independent experiments. ****** $P < 0.01$, one-way ANOVA.

774

775 **Fig. 6. PMA-induced NET formation and ROS production is inhibited by FH.**

776 **(A)** Percentage of NET formation upon 100 nM PMA treatment for 0-180 min. The extracellular
777 DNA was quantified by a plate fluorimeter after staining with 5 μM Sytox Orange. Mean \pm SEM
778 are shown from three independent measurements. **(B)** NET formation was visualized by staining
779 with 5 μM Sytox Orange. The representative microscopic images illustrate the effects of the
780 indicated treatments. The adherent cell densities are shown in the DIC images, using a 20x
781 objective. Original scale bars, 100 μm . **(C)** Neutrophils were stimulated for 3 h after allowing
782 them to adhere for 30 min. Unstimulated neutrophils in serum-free RPMI medium and
783 neutrophils incubated with 100 nM PMA served as negative and positive controls, respectively.
784 50 $\mu\text{g/ml}$ FH was either immobilized or added in solution in serum-free medium alone, or
785 together with 100 nM PMA. Data are means \pm SEM from five independent experiments. ***** $P <$
786 0.05, one-way ANOVA. **(D)** Under the same conditions, ROS production was measured using 5
787 $\mu\text{g/ml}$ DHR as a fluorescent dye. The ROS level induced by 100 nM PMA was set to 100%. ***** $P <$
788 0.05, one-way ANOVA.

789

790 **Fig. 7. NET formation and ROS production induced by fibronectin plus β -glucan is**
791 **inhibited by FH.**

792 **(A)** Neutrophils were pretreated with 1 nM fMLF and 1 mM MnCl_2 , before induction of NET by
793 immobilized fibronectin plus β -glucan. Neutrophils formed aggregates and released NET on this
794 coat after 1 h. FH had an inhibitory effect on this stimulus. The representative microscopic

795 images show cells stained for NET with 5 μ M Sytox Orange. The adherent cell densities and the
796 degree of aggregation are seen in the DIC images, taken using a 20x objective. Scale bars, 100
797 μ m. **(B)** The extracellular DNA was quantified by plate fluorimeter using 5 μ M Sytox Orange
798 staining. $**P < 0.01$, one-way ANOVA. **(C)** Cell adhesion was also measured using Cell Tracker
799 Green-loaded cells, treated as in (B). The relative fluorescence intensity of 10^6 neutrophils was
800 set to 100% and compared with that measured on the different coats to determine the adhered cell
801 rate. **(D)** Under the same conditions ROS production was assayed using 5 μ g/ml DHR. The ROS
802 level induced by 100 nM PMA was set to 100%. $*P < 0.05$, one-way ANOVA. **(E)** Lactoferrin
803 secretion from supernatants after 1 h stimulation was measured by ELISA. Data in **(B)-(E)** are
804 means \pm SEM from eight independent experiments.

805

806 **Video legends**

807

808 **Video 1. Neutrophil spreading and calcium response upon exposure to immobilized factor** 809 **H.**

810 This video shows neutrophil spreading upon immobilized FH stimulus and the changes in
811 fluorescence intensity of Fluo-4 calcium indicator during this process. The live cell imaging was
812 started immediately after the cells were placed into the coated wells, since as they reach the
813 bottom of the plate an activation stimulus is instantly provided. The focal plane was set during
814 the recording. 20 min real time events were compressed in this video.

815

816 **Video 2. Neutrophil spreading and calcium response upon exposure to immobilized BSA.**

817 This video shows neutrophil spreading upon immobilized BSA stimulus and the changes in
818 fluorescence intensity of Fluo-4 calcium indicator during this process. The recording was made
819 under the same circumstances as for Video 1.

820

Fig. 1.




Fig. 2.




Fig. 3.




Fig. 4.




Fig. 5.





Fig. 6.



Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps

Andrea E. Schneider,^a Noémi Sándor,^b Éva Kárpáti,^a Mihály Józsi^a

^a MTA-ELTE “Lendület” Complement Research Group, Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary;

^b MTA-ELTE Immunology Research Group, Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary

Corresponding author: Mihály Józsi, MTA-ELTE “Lendület” Complement Research Group, Department of Immunology, Eötvös Loránd University, Pázmány Péter sétány 1/c, H-1117 Budapest, Hungary; Phone: +36 1 3812175; Fax: +36 1 3812176; E-mail: mihaly.jozsi@gmx.net.




Figure S1. Verification of NETs.

The representative microscopic images show neutrophils stimulated with 100 nM PMA. The decondensed nuclei were counterstained with Sytox Orange (red) after 180 min incubation with PMA. After fixation, staining was performed with primary antibody directed against MPO and Alexa647-conjugated secondary antibody (green, upper panel), or with primary antibody against citrullinated histone H4 and Alexa488-conjugated secondary antibody (green, lower panel). Images were captured with 60x objective. Original scale bars, 50 μ m.